Easing Manufacturing Bottlenecks to Meet the Potential of mRNA
Easing Manufacturing Bottlenecks to Meet the Potential of mRNA
Sponsored by:
Sponsored by:
More from Manufacturing
• By
Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.
• By
Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."
More from Business
Sponsored by:
Delve into the challenges facing the NHS, from rising medicine costs to supply shortages, and how generics and branded generics can provide solutions for a more sustainable healthcare system
Sponsored by:
Learn about the critical role the right CRO plays in successfully navigating the significant drug development opportunities in Japan.
Sponsored by:
Access key stats from biotechs on the latest trends impacting oncology R&D, including therapeutic pipelines and clinical trial challenges, AI/ML, and a future outlook on innovation.
Sponsored by:
Gain exclusive insights into the biggest challenges biotechs face in oncology and uncover the latest opportunities to accelerate drug development.